Relative Bioavailability of Single Oral Dose of BI 113608 When Administered Alone or in Combination With Multiple Oral Doses of Ketoconazole or Voriconazole in Healthy Male Subjects (an Open-label, Randomised, Three-period Cross-over Trial)
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2017
Price : $35 *
At a glance
- Drugs BI 113608 (Primary) ; Ketoconazole; Voriconazole
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Mar 2013 Planned End Date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov record.
- 06 Mar 2013 Planned End Date changed from 1 Apr 2013 to 1 Mar 2013 according to the ClinicalTrials.gov record.